KMG Fiduciary Partners LLC Buys New Position in Centene Corporation $CNC

Key Points

• KMG Fiduciary Partners purchased 56,158 Centene shares worth approximately $3.49 million during the third quarter. Institutional investors collectively own 93.63% of the company.
• Centene reported quarterly adjusted earnings of $2.51 per share, exceeding estimates of $1.09, while revenue rose 9.9% year over year to $53.58 billion.
• The stock recently traded near its 52-week high at $68.89, while analysts maintain a consensus “Hold” rating and an average price target of $70.05.

KMG Fiduciary Partners LLC bought a new stake in shares of Centene Corporation (NYSE:CNC - Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 56,158 shares of the company's stock, valued at approximately $3,489,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Silicon Valley Capital Partners purchased a new stake in Centene in the 2nd quarter worth $25,000. North Point Portfolio Managers Corp OH purchased a new position in Centene during the third quarter valued at $25,000. Toth Financial Advisory Corp purchased a new position in Centene during the third quarter valued at $30,000. MidFirst Bank acquired a new stake in shares of Centene in the second quarter valued at about $32,000. Finally, Bayban acquired a new stake in shares of Centene in the fourth quarter valued at about $33,000. Institutional investors and hedge funds own 93.63% of the company's stock.

Centene Price Performance

Centene stock opened at $68.89 on Wednesday. Centene Corporation has a 52-week low of $31.63 and a 52-week high of $69.70. The firm has a market capitalization of $34.03 billion, a price-to-earnings ratio of -6.60, a PEG ratio of 0.42 and a beta of 1.13. The company has a fifty day simple moving average of $65.15 and a 200-day simple moving average of $59.07. The company has a quick ratio of 1.15, a current ratio of 1.15 and a debt-to-equity ratio of 0.71.

Centene (NYSE:CNC - Get Free Report) last issued its earnings results on Monday, July 27th. The company reported $2.51 EPS for the quarter, beating analysts' consensus estimates of $1.09 by $1.42. The business had revenue of $53.58 billion during the quarter, compared to analysts' expectations of $47.64 billion. Centene had a negative net margin of 2.51% and a positive return on equity of 12.12%. The company's quarterly revenue was up 9.9% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.16) earnings per share. On average, equities analysts anticipate that Centene Corporation will post 4.89 EPS for the current fiscal year.

Centene News Roundup

Here are the key news stories impacting Centene this week:

• Positive Sentiment: Centene will launch a nationwide performance-based Gold Card Program in November 2026. The program will initially cover more than 160,000 qualifying providers and streamline prior-authorization reviews for certain outpatient services while maintaining clinical and quality standards. Investors may view the initiative as a way to reduce administrative friction, improve provider relationships and support operating efficiency. Centene to Launch Nationwide Gold Card Program for Qualifying Providers
• Positive Sentiment: Additional bullish discussion highlighted Centene’s redemption of its remaining 2027 notes, expansion of primary-care capabilities and the Gold Card rollout. These developments reinforce a recovery narrative centered on lower debt, simpler administration and improving margins ahead of the company’s late-October earnings report. Centene Is Up After Gold Card, Debt Redemption and Primary Care Expansion News
• Positive Sentiment: PA Health & Wellness, a Centene subsidiary, was recognized by the National Committee for Quality Assurance as one of the top 17 Medicaid health plans in the United States for the second consecutive year. The recognition supports Centene’s quality credentials in its core Medicaid business, although the direct financial impact is limited. PA Health & Wellness Earns National Recognition Among Top Medicaid Health Plans
• Neutral Sentiment: CEO Sarah London said artificial intelligence should improve access for Medicaid patients, including those in medical-care deserts, rather than merely reduce billing costs. The comments support Centene’s longer-term innovation strategy, but no specific financial targets or implementation details were announced. Centene CEO Sarah London Discusses Medicaid and AI
• Neutral Sentiment: Analyst commentary from Zacks favored Centene over Molina Healthcare, citing CNC’s diversified business, improving margins, lower valuation and stronger expected earnings prospects. However, the cited median analyst price target of $62 is below the stock’s recent trading level, potentially limiting near-term upside.
• Negative Sentiment: Reported insider activity over the past six months consisted of sales rather than purchases, including sales by executives Christopher Koster and Kenneth Burdick. Insider selling does not necessarily signal deteriorating fundamentals, but it is a modest sentiment headwind.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. Raymond James Financial set a $75.00 price target on shares of Centene in a research report on Tuesday, July 7th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Centene in a report on Friday. Stifel Nicolaus set a $79.00 price objective on Centene in a research note on Monday, August 3rd. UBS Group set a $79.00 price objective on Centene in a research note on Tuesday, August 18th. Finally, Wells Fargo & Company set a $69.00 target price on Centene and gave the company an "equal weight" rating in a report on Monday, July 13th. Nine investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $70.05.

Insider Transactions at Centene

In other Centene news, General Counsel Christopher Koster sold 56,500 shares of the stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $66.90, for a total value of $3,779,850.00. Following the completion of the sale, the general counsel owned 248,854 shares in the company, valued at approximately $16,648,332.60. This represents a 18.50% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.37% of the company's stock.

Centene Profile

Centene Corporation NYSE: CNC is a healthcare enterprise that provides health insurance and related services, primarily through government-sponsored programs. Its offerings include Medicaid plans, Medicare products, health plans sold through the Affordable Care Act marketplace, and services for military families through government-sponsored healthcare programs.

The company also provides pharmacy, behavioral health, specialty healthcare, care management and administrative services through various subsidiaries and partner organizations.

Want to see what other hedge funds are holding CNC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Centene Corporation (NYSE:CNC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.